The USA’s Institute for Bioscience and Biotechnology Research (IBBR) is interested in proposals to lease a biomanufacturing facility configured to produce biologicals under current Good Manufacturing Practices (cGMP) conditions in compliance with Food and Drug Administration requirements for Phase I/II clinical trials.
The facility is also equipped to perform process development research, pre-clinical manufacturing for material necessary to conduct IND-enabling toxicology studies, Point of Concept (POC) studies, and process demonstration in advance of GMP manufacturing.
The IBBR is a joint research enterprise between the University of Maryland and the National Institute of Standards and Technology.
For additional information and to schedule a tour of the GMP facility, please contact:
Viqar Aslam
Director Business Development and Strategy
9600 Gudelsky Drive
Rockville, MD 20850
Phone: 240-314-6273
Email: vaslam@umd.edu
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze